NewsHalper Sadeh LLC Investigates Arcosa, Crinetics Pharmaceuticals, and Leggett & Platt Over Proposed Sale TransactionsHalper Sadeh LLC Investigates Arcosa, Crinetics Pharmaceuticals, and Leggett & Platt Over Proposed Sale Transactions
Halper Sadeh LLC is investigating Arcosa, Inc., Crinetics Pharmaceuticals, Inc., and Leggett & Platt, Incorporated for potential federal securities law violations and fiduciary duty breaches tied to their proposed sale transactions. Arcosa's deal involves a sale to CRH at $150.00 per share, Crinetics Pharmaceuticals is being acquired by Vertex Pharmaceuticals Incorporated for $85.00 per share in cash, and Leggett & Platt's transaction with Somnigroup International Inc. offers 0.1455 shares of Somnigroup common stock per share, with Leggett & Platt shareholders set to own approximately 9% of the combined company. The firm may pursue increased consideration, additional disclosures, or other shareholder relief.
*this image is generated using AI for illustrative purposes only.
Investor rights law firm Halper Sadeh LLC has announced it is investigating three publicly listed companies — Arcosa, Inc., Crinetics Pharmaceuticals, Inc., and Leggett & Platt, Incorporated — for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders. The investigations relate to proposed sale transactions involving each company and raise concerns about whether shareholders are receiving fair value and adequate disclosures.
Transactions Under Scrutiny
The firm's investigations span three separate proposed deals across different sectors. Key details of each transaction are outlined below:
| Company: | Acquirer: | Deal Terms |
|---|---|---|
| Arcosa, Inc. | CRH | $150.00 per share |
| Crinetics Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated | $85.00 per share in cash |
| Leggett & Platt, Incorporated | Somnigroup International Inc. | 0.1455 shares of Somnigroup common stock per Leggett & Platt share |
In the case of Leggett & Platt, upon closing of the proposed transaction, Leggett & Platt shareholders will own approximately 9% of the combined company.
Key Concerns Raised
Halper Sadeh LLC has highlighted several areas of concern across these transactions:
- Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
- The proposed transactions may contain terms that could limit superior competing offers.
- Shareholders may not have received sufficient disclosures and information to make fully informed decisions.
Potential Relief Sought
On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits. The firm represents investors globally who have been affected by securities fraud and corporate misconduct, and states that its attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Shareholders of Arcosa, Crinetics Pharmaceuticals, and Leggett & Platt are encouraged to contact the firm to discuss their rights and options. The firm indicates it would handle any matter on a contingent fee basis, whereby shareholders would not be responsible for out-of-pocket payment of legal fees or expenses.
How might the legal scrutiny from Halper Sadeh LLC impact the likelihood of CRH, Vertex, and Somnigroup closing their respective acquisition deals?
Could these investigations lead to a broader market trend where acquirers face increased pressure to improve deal terms and disclosures for minority shareholders?
What specific regulatory or corporate governance reforms might emerge if shareholders successfully secure relief in these cases?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
